EADV 2025: Guttman-Yassky has great confidence in the future of agents that block the OX40 pathway, suggesting that they have the potential for disease modification.
Emma Guttman-Yassky, MD
Advertisement
Articles by Emma Guttman-Yassky, MD
Advertisement
Latest Updated Articles
When We Say "OX40 Inhibition," What Do We Mean? Emma Guttman-Yassky, MD, PhD, ExplainsPublished: September 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
2
Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154
3
Cannabis Extract Provides LBP Relief Superior to Opioids Over 12 Months in Phase 3 Clinical Trial
4
Measles Outbreak Fails to Push MMR Rates to Herd Immunity Levels, Study Reveals
5
